The real differentiator may be the metabolic preservation effects seen with CagriSema in preclinical models, but human data confirming this advantage is still limited
As of 2025, BPC-157 remains available mostly on the black market through overseas companies or dubious online shops but reputable U.S
cDNA microarray analysis of rat Achilles tendon fibroblasts identified the growth hormone receptor as one of the most abundantly up-regulated genes following exposure to the peptide, with concentration- and time-dependent increases confirmed at both mRNA and protein level, and downstream Janus kinase 2 activation observed on subsequent growth hormone stimulation [3]
[1] Mechanistically it works along a single hormonal pathway the amylin system which is what distinguishes it from the multi-receptor incretin agonists it is often compared with
Both are dominated by gastrointestinal adverse events nausea, constipation, diarrhea, vomiting that are mostly mild-to-moderate and dose-related
Research in animal models shows impressive results